Lineage Cell Therapeutics Stock Performance
| LCTX Stock | USD 0.61 0.01 1.67% |
The company secures a Beta (Market Risk) of 1.51, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lineage Cell will likely underperform. At this point, Lineage Cell Therapeutics has a negative expected return of -0.4%. Please make sure to verify Lineage Cell's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Lineage Cell Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lineage Cell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 3:1 | Last Split Date 1997-10-31 |
1 | OpRegen Phase 12a Results to Be Featured at International Society for Stem Cell Research 2024 Copenhagen International Symposium - StockTitan | 09/25/2024 |
2 | NovoCure Surges 10.7 percent Is This an Indication of Further Gains | 10/16/2024 |
3 | Lineage Cell Therapeutics GAAP EPS of -0.02 beats by 0.02, revenue of 3.77M beats by 2.88M | 11/14/2024 |
4 | Lineage Cell Therapeutics tumbles after pricing 66M securities offering | 11/20/2024 |
5 | Acquisition by Mulroy Michael H. of 40000 shares of Lineage Cell at 0.566 subject to Rule 16b-3 | 11/22/2024 |
6 | Acquisition by Samuel George A. Iii of 15000 shares of Lineage Cell at 0.6 subject to Rule 16b-3 | 11/26/2024 |
7 | Lineage Cell Therapeutics stock rating holds at Buy, Phase 2a data sparks target rise - Investing.com | 12/04/2024 |
| Begin Period Cash Flow | 11.9 M |
Lineage |
Lineage Cell Relative Risk vs. Return Landscape
If you would invest 89.00 in Lineage Cell Therapeutics on September 12, 2024 and sell it today you would lose (28.00) from holding Lineage Cell Therapeutics or give up 31.46% of portfolio value over 90 days. Lineage Cell Therapeutics is currently does not generate positive expected returns and assumes 5.8757% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Lineage, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lineage Cell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lineage Cell's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lineage Cell Therapeutics, and traders can use it to determine the average amount a Lineage Cell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0686
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LCTX |
Estimated Market Risk
| 5.88 actual daily | 52 52% of assets are less volatile |
Expected Return
| -0.4 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lineage Cell is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lineage Cell by adding Lineage Cell to a well-diversified portfolio.
Lineage Cell Fundamentals Growth
Lineage Stock prices reflect investors' perceptions of the future prospects and financial health of Lineage Cell, and Lineage Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lineage Stock performance.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (4.17) % | ||||
| Current Valuation | 102.13 M | ||||
| Shares Outstanding | 220.42 M | ||||
| Price To Earning | 3.62 X | ||||
| Price To Book | 2.00 X | ||||
| Price To Sales | 21.64 X | ||||
| Revenue | 8.95 M | ||||
| Gross Profit | 13.97 M | ||||
| EBITDA | (24.04 M) | ||||
| Net Income | (21.49 M) | ||||
| Cash And Equivalents | 66.36 M | ||||
| Cash Per Share | 0.39 X | ||||
| Total Debt | 2.95 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 3.01 X | ||||
| Book Value Per Share | 0.36 X | ||||
| Cash Flow From Operations | (28.57 M) | ||||
| Earnings Per Share | (0.10) X | ||||
| Market Capitalization | 133.88 M | ||||
| Total Asset | 101.02 M | ||||
| Retained Earnings | (384.86 M) | ||||
| Working Capital | 20.48 M | ||||
| Current Asset | 12.84 M | ||||
| Current Liabilities | 2.74 M | ||||
About Lineage Cell Performance
Evaluating Lineage Cell's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Lineage Cell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lineage Cell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.52) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.34) | (0.32) |
Things to note about Lineage Cell Therapeutics performance evaluation
Checking the ongoing alerts about Lineage Cell for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lineage Cell Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lineage Cell generated a negative expected return over the last 90 days | |
| Lineage Cell has high historical volatility and very poor performance | |
| Lineage Cell has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 8.95 M. Net Loss for the year was (21.49 M) with profit before overhead, payroll, taxes, and interest of 13.97 M. | |
| Lineage Cell Therapeutics currently holds about 66.36 M in cash with (28.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Lineage Cell has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Lineage Cell Therapeutics stock rating holds at Buy, Phase 2a data sparks target rise - Investing.com |
- Analyzing Lineage Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lineage Cell's stock is overvalued or undervalued compared to its peers.
- Examining Lineage Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lineage Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lineage Cell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lineage Cell's stock. These opinions can provide insight into Lineage Cell's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.